Journal profile · ONCOLOGY
Oncology Research and Treatment
ISSN 2296-5270 · eISSN 2296-5262 · S. Karger AG · GERMANY
Oncology Research and Treatment: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 1.29; hybrid open access; median 119 days to acceptance (97 articles, last 24 months); 125 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Oncology Research and Treatment is published by S. Karger AG and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Human auditory perception and evaluation, Diverse Scientific and Economic Studies and Educational Robotics and Engineering, together about 35.1% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
With the first issue in 2014, the journal 'Onkologie' has changed its title to 'Oncology Research and Treatment'. By this change, publisher and editor set the scene for the further development of this interdisciplinary journal. The English title makes it clear that the articles are published in English – a logical step for the journal, which is listed in all relevant international databases. For excellent manuscripts, a 'Fast Track' was introduced: The review is carried out within 2 weeks; after acceptance the papers are published online within 14 days and immediately released as 'Editor’s Choice' to provide the authors with maximum visibility of their results. Interesting case reports are published in the section 'Novel Insights from Clinical Practice' which clearly highlights the scientific advances which the report presents.
Source: LetPub
Research area (LetPub): ONCOLOGY
Main research topics OpenAlex counts of recent articles; shares are approximate
- Human auditory perception and evaluationEngineering14.7%
- Diverse Scientific and Economic StudiesEconomics, Econometrics and Finance12.9%
- Educational Robotics and EngineeringComputer Science7.5%
- Lung Cancer Treatments and MutationsMedicine5.1%
- Cancer Treatment and PharmacologyMedicine4.4%
- Biosimilars and Bioanalytical MethodsImmunology and Microbiology4.3%
- Colorectal Cancer Treatments and StudiesMedicine3.9%
- Cancer Immunotherapy and BiomarkersMedicine3.5%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 1.29LetPub ·
- CiteScore 2026-06
- 2.4LetPub ·
- SJR 2026-06
- 0.48LetPub ·
- SNIP 2026-06
- 0.45LetPub ·
- h-index
- 43LetPub ·
- h-index
- 63OpenAlex ·
- i10-index
- 875OpenAlex ·
- 2-year mean citedness
- 1.11OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 16.22%LetPub ·
Volume
- Articles per year
- 67LetPub ·
Articles by year OpenAlex count · 3,710 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 27 | 8 | 5 |
| 2025 | 125 | 47 | 100 |
| 2024 | 112 | 38 | 188 |
| 2023 | 106 | 31 | 250 |
| 2022 | 127 | 42 | 490 |
| 2021 | 146 | 43 | 894 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
119 daysMedian, submission to acceptance · P25–P75 71 days – 168 days
- Acceptance to online
- median 16 days (97 articles)
- Submission to online
- median 136 days
- Sample
- 97 articles with submission and acceptance dates (119 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Policy excerpts from the journal's websitePeer review
- Peer review
Peer-reviewed publishing; Open Access and hybrid publications Model summary
Karger publishes nearly 100 peer-reviewed medical journals and 9,000 books, including Open Access and hybrid publications.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- S. Karger AG
- Country or region
- GERMANY
- Language
- English
- ISSN
- 2296-5270
- Electronic ISSN
- 2296-5262
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Oncology Research and Treatment
What CAS zone is Oncology Research and Treatment in?
In the 2025 upgraded edition of the CAS Journal Ranking, Oncology Research and Treatment is in Zone 4 of Medicine, and in Zone 4 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Oncology Research and Treatment?
The latest impact factor listed by LetPub is 1.29; CiteScore 2.4, h-index 63.
How long does peer review take at Oncology Research and Treatment?
Based on the dates recorded on 97 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 119 days (interquartile range 71–168 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Oncology Research and Treatment?
According to LetPub and DOAJ records, Oncology Research and Treatment is indexed in SCIE and Scopus.
Is Oncology Research and Treatment open access, and what is the APC?
Oncology Research and Treatment is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .